Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5785 | pep2-SVKE |
| Inactive control peptide analog of pep2-SVKI, an inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluR2 AMPA receptor subunit. | |
| BCC5786 | pep2-EVKI |
| Inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluA2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD). | |
| BCC5787 | pep2-AVKI |
| Inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluA2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD). | |
| BCC5791 | CRF (6-33) |
| Corticotropin-releasing factor binding protein (CRFBP) inhibitor peptide; displaces CRF from CRFBP. Suppresses body weight gain and increases motor activity in obese rats in vivo. | |
| BCC5792 | Sauvagine |
| Corticotropin-releasing factor (CRF) receptor agonist. Ki values are 9.4, 9.9, and 3.8 nM for inhibition of 125I-[D-Tyr1]astressin binding to hCRF-R1, rCRF-R2a and mCRF-R2b respectively. | |
| BCC5793 | [Orn8]-Urotensin II |
| Inhibitor of glycogen synthase kinase-3 (GSK-3); derived from FRAT1, the mammalian version of GSK-3-binding protein. Binds to GSK-3, inhibiting its interaction with axin, and also blocks GSK-3-catalyzed phosphorylation of axin and β-catenin. Does not affect GSK-3-mediated phosphorylation of glycogen synthase or eIF2B. | |
| BCC5794 | 2-Methylthioadenosine diphosphate trisodium salt |
| Potent purinergic agonist displaying selectivity for P2Y1, P2Y12 and P2Y13 receptors (pEC50 = 8.29 and 9.05 for P2Y1 and P2Y12, EC50 = 19 nM for P2Y13). Induces aggregation of, and inhibits cAMP accumulation in, platelets in vitro. | |
| BCC5796 | Urotensin II (human) |
| Potent endogenous peptide agonist for the urotensin-II receptor (EC50 = 0.1 nM). Displays arterio-selective vasoconstriction and vasodilatation in mammals in vitro and in vivo, effects which vary between species. Also has been shown to mediate bronchoconstriction. | |
